Objectives: Asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) is recognized increasingly as a distinct clinical entity and is associated with higher comorbidities compared with patients with asthma and COPD alone. Little is known about the leading causes of death related to ACO in the US general population, however. Our aim was to define the causes of mortality among patients with ACO compared with asthma and COPD in the US population.
A sthma and chronic obstructive pulmonary disease (COPD) are problematic chronic airway diseases with a high prevalence. 1 These diseases have clear differences, but some patients present with features of both. 2, 3 The term "asthma-COPD overlap" (ACO) has been identified as an entity that shares clinical features with both asthma and COPD. 4, 5 The 2015 Global Initiative for Chronic Obstructive Lung Disease guidelines suggested that ACO be recognized as a distinct clinical entity. Although both the Global Initiative for Asthma and Global Initiative for Chronic Obstructive Lung Disease provide a clinical description of ACO, they acknowledge that the ACO definition is difficult to apply in clinical practice. Furthermore, studies have used different criteria, including self-reported, physician-diagnosed asthma and COPD. [6] [7] [8] [9] [10] [11] [12] Despite methodological differences, these studies have demonstrated that patients with ACO have a poorer healthrelated quality of life, greater disability, more comorbidities, more emergency department (ED) visits or hospitalizations, higher exacerbation rates, and higher healthcare costs than subjects with asthma or COPD alone. 8, 11, 13, 14 ACO mortality has been evaluated less frequently. A previous study in the National Health and Nutrition Examination Survey III (NHANES III) population showed that the concurrent diagnosis of airflow limitation and asthma was associated with higher mortality rates than either self-reported asthma or COPD alone. 15 In contrast, several studies have reported that the concomitant diagnosis of asthma does not increase mortality in patients with COPD. 16 Because of conflicting evidence, there is a need to further characterize mortality and its causes in ACO. The NHANES III study provides information from a large cohort of individuals before the diagnosis of ACO was envisioned. This provides the opportunity to evaluate the risk and causes of mortality in ACO.
The aim of the present study was to investigate leading causes of death among patients with ACO and compare these with patients with asthma and COPD in the US population.
Methods
We conducted an observational study using data from the publicly available NHANES III dataset. NHANES III is nationally representative of the civilian noninstitutionalized population in the United States and is conducted by the National Center for Health Statistics of the Centers for Disease Control and Prevention. The participants were selected by a stratified multistage probability design that included interviews, physical examinations, pulmonary function testing, and blood testing. The methods are described elsewhere. 17, 18 The data were collected from 1988 to 1994 and consisted of 33,994 participants. They were linked to records in the National Death Index followed through 2011. A complete description of the linkage methodology can be found online. 19 The study was approved by the National Center for Health Statistics institutional review board. This analysis was limited to participants aged 35 years and older who completed a baseline survey, had their vital status determined at the end of follow-up, and had a spirometry test marked as reliable by two quality-control technicians.
A history of COPD was defined as an affirmative response to the question "Has a doctor ever told you that you have chronic bronchitis or emphysema?" plus "evidence of obstruction by spirometry (FEV 1 [forced expiratory volume in one second]/FVC [forced vital capacity] <70%)." A history of asthma was defined as an affirmative response to the questions "Has a doctor ever told you that you have asthma" and "Do you still have asthma?" A diagnosis of ACO was defined if the participant had been diagnosed as having COPD with evidence of obstruction on spirometry plus a history of physician diagnosis of past or current asthma. A participant's age was defined as his or her age in years as reported at the baseline examination. Race/ethnicity was categorized as non-Hispanic white, non-Hispanic black, Mexican American, and other. Education level was categorized as <12 years, 12 years, and >12 years of education. A history of smoking was categorized as never, past, or current. Marital status was categorized into three levels: married, never married, or separated.
Statistical Analysis
We examined the distributions and selected characteristics among study respondents aged 35 years and older among people with asthma, ACO, or COPD, and those without lung disease. Following NHANES III analytic guidelines, the survey weight variables were used to account for differential probabilities of selection, nonresponse, and complex survey design. Group differences in proportions among categorical variables were analyzed using a χ 2 test and summarized as percentages. Differences in means among continuous variables were analyzed using the Student t test and summarized as mean score ± standard deviation as appropriate. Individual differences among categories of lung disease were corrected for multiple comparison by Bonferroni methods. We also explored six causes of death among lung disease categories. Logistic regression analysis was used to model three leading causes of death, including cardiovascular disease, malignancy, and chronic lower respiratory disease, adjusting for differences among key variables, including demographic factors, socioeconomic factors, and smoking status. A procedure in the statistical software package SAS version 9.4 (SAS Institute, Cary, NC), called PROCSURVEY LOGISTIC was used to estimate the odds ratios and 95% confidence intervals for leading causes of death in people with asthma, COPD, or ACO, and those without lung disease. The differences were considered significant at P < 0.05.
Results
NHANES III had 33,994 participants. Our study had 4434 participants after excluding those 35 years of age and younger, those with incomplete and unreliable spirometry, and those without a known cause of death. The study population was stratified into four groups: asthma (2.7%), ACO (2.8%), COPD (7.6%), and no obstructive lung disease (86.8%). Figure 1 shows the flowchart for respondents included in our study.
The baseline characteristics of the selected participants stratified by type of respiratory disease are presented in the Table. The COPD group was older (69.7 ± 10.9 years) as compared with the group with ACO (65.4 ± 11.6 years) and the group with asthma (65.7 ± 13.7 years; P = 0.001). Body mass index (BMI) was lower in those with COPD and higher in those with asthma compared with the control population (P < 0.0001 for each). Those with ACO had a BMI that lay between the BMIs of patients with asthma and COPD but was similar to that of the control population. Much of the study population was non-Hispanic white in all four groups, with the highest proportion in the group with COPD (75.9%). The proportions of African Americans were 37.5%, 26.2%, 13.5%, and 23.3% in asthma, ACO, COPD, and those without any obstructive lung disease, respectively. The proportion of races/ethnicity differed significantly in all four groups (P = 0.0002). The education level was significantly different between the groups (P = 0.02), with the majority having had a formal education of <12 years. The marital status did not differ significantly among the groups (P = 0.51). The proportion of former smokers was highest in those with ACO (44.4%); the proportion of current smokers was highest in those with COPD (32.9%). The smoking status was significantly different among the four groups (P < 0.0001). Figure 2 shows all-cause mortality in the NHANES III study population. Deaths from cardiovascular disease were proportionately the highest cause in all groups, ranging from 23.8% to 25.8%. Deaths from cancer were the second leading cause of death in all of the groups. The group with ACO had a disproportionately higher number of deaths from chronic lower respiratory disease (21.4%) as compared with those with asthma (9.5%) and those without obstructive lung disease (2.9%). There was no significant difference in respiratory disease-related mortality between the ACO and COPD groups after adjusting for age, sex, and smoking status (P = 0.16) Fig. 3 . The deaths from cerebrovascular disease were not significantly different among patients with asthma (8.7%), ACO (4.8%), and COPD (5.6%), and those without obstructive lung disease (7.4%; P = 0.91).
Discussion
This study used population-based data collected for NHANES III to assess the impact of chronic respiratory diseases and compare the leading causes of death in obstructive lung diseases in the US general population. Our analysis adds to the growing body of evidence demonstrating adverse outcomes associated with ACO and COPD. These data show that cardiovascular diseases, malignancies, and chronic lower respiratory diseases are the three leading causes of death among patients with asthma, ACO, and COPD. This is consistent with data in the general US population and worldwide. [20] [21] [22] There are several studies reporting causes of death in patients with obstructive lung diseases. A Spanish study in 2068 patients with asthma showed that a subgroup of patients with COPD frequently died of malignancy, acute respiratory failure, and cardiovascular disease. 23 In Japanese patients with ACO, malignancy was the most frequent cause of death, 24 whereas cardiovascular disease and malignancy were the most common causes of death in our study. To a large extent this variation in the disease prognosis likely can be explained by behavioral risk factors, including tobacco use, education, physical activity, and BMI. 22 An integrative effort to promote the development of strategies and mitigate risk factors may help to reduce mortality and the burden of these chronic diseases.
We also found that deaths caused by cardiovascular disease and malignancy were not significantly different among the respiratory disease categories; however, deaths from chronic respiratory disease are higher in ACO. This finding is consistent with the results in the Copenhagen City Heart Study. 25 One possible explanation for this finding is that those with frequent ED visits from respiratory causes have more opportunities to acquire a dual diagnosis. 2, [26] [27] [28] Physiologically, patients with bronchial hyperresponsiveness have a more rapid decline in forced expiratory volume in one second and more exacerbation, which affect respiratory-specific mortality. The overlap between asthma and COPD remains common in older patients in primary care and is frequently underrecognized and undertreated. 3 It often is challenging for clinicians to make a correct diagnosis because of the overlap in symptoms, atypical presentation, age-related reduction of dyspnea perception, and associated comorbidities.
Another reason for increased respiratory death may be environmental exposure to smoke, air pollution, and organic volatiles. A previous study demonstrated that the COPD patient population with a concurrent diagnosis of asthma responded differently to asthmagens. Those with severe disease were likely to report being affected by volatile organic matter. 29 These triggers affect patients with COPD and asthma, thereby causing exacerbations. 30 Such exposures in older people lead to ED visits and admission to the intensive care unit and therefore pose a greater risk of death from respiratory causes. 31 The major strength of our study is that the study population of NHANES is representative of the US population; however, with any observational study, our analysis was subject to limitations. ACO is a relatively new entity that is not recognized within the baseline years of NHANES. As such, we are left with a posthoc disease characterization that is common to all current ACO studies. Although COPD is diagnosed by high-quality spirometry in all of the patients in this analysis, asthma is a clinical diagnosis. We believe it is unlikely that a mortality-focused study using the methacholine challenge or a more specific asthma physiology will be conducted in the next 20 years. We coupled spirometry with a self-reported physician diagnosis of both COPD and asthma to define this cohort with the most specificity possible. Several studies have reported that a self-reported physician diagnosis can reliably predict obstructive lung disease and usually is consistent with the diagnosis in the medical chart. [32] [33] [34] Bias could arise from an incorrect cause of death for patients with two or more respiratory illnesses. The presence of chronic lower respiratory disease may artificially raise the frequency of respiratory causes of death when the cause of death was not obvious. There are likely other confounding factors that were not considered in our analysis, which could introduce bias such as factors arising from survey nonresponse and selection.
Traditionally, clinical trials studying COPD or asthma have excluded patients with ACO, making it difficult to understand the pathophysiology and efficacy of respiratory treatment in this cohort. Future research will first attempt to develop biomarker signatures that define these patients and their clinical phenotypes. When blood biomarkers from historical cohorts can accurately define the ACO population, longitudinal clinical outcomes, possibly including mortality, can be revisited. Efforts are defining the role of immunoglobulin E, sputum, and blood eosinophils in COPD cohorts.
Conclusions
Although the leading causes of death in the United States are cardiovascular disease and malignancy, these are not different in asthma, ACO, and COPD. A higher proportion of mortality in ACO and COPD is attributed to chronic lung disease. As such, primary care physicians should be aware that asthma that has persistent obstruction on spirometry despite therapy (ACO) requires more aggressive care. We await a better understanding of the fundamental biology underlying ACO and the development of potential biomarkers. These biomarkers will aid in distinguishing patients with similar clinical syndromes of different etiology and will allow personalized medicine approaches for the development of highly targeted therapies.
